Published in J Antibiot (Tokyo) on September 01, 1987
Kidney transplantation under FK 506. JAMA (1990) 7.45
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet (2000) 3.64
FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1991) 2.97
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol (1999) 2.57
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut (2006) 1.75
Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol (1999) 1.64
Gene activation by interaction of an inhibitor with a cytoplasmic signaling protein. Proc Natl Acad Sci U S A (2002) 1.39
Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. Immunology (1989) 1.22
Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. Mol Cell Biol (1991) 1.22
Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One (2009) 1.22
Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev (1999) 1.21
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther (2010) 1.12
Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology (1992) 1.12
Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol (1990) 1.11
Cancer wars: natural products strike back. Front Chem (2014) 1.11
Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? Cell Commun Signal (2009) 1.06
Screening of small molecule interactor library by using in-cell NMR spectroscopy (SMILI-NMR). J Med Chem (2009) 1.05
On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease. PLoS One (2008) 1.04
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol (1993) 1.02
Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech (2008) 1.02
Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J (2013) 1.01
[Systemic immunosuppressives after penetrating keratoplasty]. Ophthalmologe (2007) 0.99
Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc (1991) 0.98
The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation (1992) 0.98
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor. J Ind Microbiol Biotechnol (2009) 0.97
Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol (2005) 0.96
Discovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infection. J Antibiot (Tokyo) (2016) 0.95
Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res (2014) 0.95
Microbial peptidyl-prolyl cis/trans isomerases (PPIases): virulence factors and potential alternative drug targets. Microbiol Mol Biol Rev (2014) 0.93
Recent advances in the treatment of graft-versus-host disease. Clin Med Res (2004) 0.92
Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats. Br J Ophthalmol (2006) 0.92
Phage p1-derived artificial chromosomes facilitate heterologous expression of the FK506 gene cluster. PLoS One (2013) 0.91
Exploiting orthogonally reactive functionality: synthesis and stereochemical assignment of (-)-ushikulide A. J Am Chem Soc (2008) 0.91
Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. Immunology (1990) 0.90
Immunosuppressants affect human neural stem cells in vitro but not in an in vivo model of spinal cord injury. Stem Cells Transl Med (2013) 0.90
On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS One (2008) 0.89
Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Devel Ther (2013) 0.89
Aqueous humor and serum penetration of tacrolimus after topical and oral administration in rats: an absorption study. Clin Ophthalmol (2007) 0.89
Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy. Curr Neuropharmacol (2013) 0.89
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol (1991) 0.88
Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. Immunology (1989) 0.88
Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). Protein Sci (1995) 0.87
Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun (2009) 0.87
Enhancement of FK506 production by engineering secondary pathways of Streptomyces tsukubaensis and exogenous feeding strategies. J Ind Microbiol Biotechnol (2013) 0.86
FK 506 inhibits the development of transplant arteriosclerosis. Transplant Proc (1991) 0.86
Discovery of novel drug targets and their functions using phenotypic screening of natural products. J Ind Microbiol Biotechnol (2015) 0.86
Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech (2012) 0.86
A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins. Antimicrob Agents Chemother (2013) 0.86
Biotic acts of antibiotics. Front Microbiol (2013) 0.86
Stereospecific cross-coupling reactions of aryl-substituted tetrahydrofurans, tetrahydropyrans, and lactones. J Am Chem Soc (2014) 0.86
Cyclophilin-dependent stimulation of transcription by cyclosporin A. Proc Natl Acad Sci U S A (1993) 0.85
Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol (2014) 0.85
Roles of fkbN in positive regulation and tcs7 in negative regulation of FK506 biosynthesis in Streptomyces sp. strain KCTC 11604BP. Appl Environ Microbiol (2012) 0.85
Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol (2015) 0.85
Specific acceptance of fetal bowel allograft in mice after combined treatment with anti-intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 antibodies. Ann Surg (1996) 0.85
FK 506 and autoimmune disease: perspective and prospects. Autoimmunity (1992) 0.85
FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. Immunology (1990) 0.85
FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85
Interaction between FK 506 and cyclosporine in dogs. Transplant Proc (1991) 0.84
Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma (2013) 0.84
Effects of a novel immunosuppressive agent, FK506, on human B cell activation. Clin Exp Immunol (1990) 0.83
FK506 augments activation-induced programmed cell death of T lymphocytes in vivo. J Clin Invest (1995) 0.83
Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. Transplantation (1990) 0.83
Draft genome of Streptomyces tsukubaensis NRRL 18488, the producer of the clinically important immunosuppressant tacrolimus (FK506). J Bacteriol (2012) 0.82
Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. Br J Pharmacol (1993) 0.82
Structural alterations in the seminiferous tubules of rats treated with immunosuppressor tacrolimus. Reprod Biol Endocrinol (2009) 0.82
Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol (2012) 0.82
Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des (2011) 0.82
Effects of FK506 on ca release channels (review). Perspect Medicin Chem (2008) 0.82
Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation (1994) 0.81
FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. J Bacteriol (1992) 0.81
Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J (2013) 0.81
Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. Drug Des Devel Ther (2015) 0.81
FK506 maturation involves a cytochrome p450 protein-catalyzed four-electron C-9 oxidation in parallel with a C-31 O-methylation. J Bacteriol (2013) 0.80
Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology (1995) 0.80
Effects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cells. J Periodontal Implant Sci (2012) 0.80
cADP-ribose potentiates cytosolic Ca2+ elevation and Ca2+ entry via L-type voltage-activated Ca2+ channels in NG108-15 neuronal cells. Biochem J (2000) 0.80
The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. Br J Pharmacol (2012) 0.80
Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med (1993) 0.80
Strain development of Streptomyces sp. for tacrolimus production using sequential adaptation. J Ind Microbiol Biotechnol (2009) 0.79
FK506: the promise and the paradox. Clin Exp Immunol (1991) 0.79
Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. Acta Pharmacol Sin (2011) 0.79
Therapeutic Strategies to Treat Dry Eye in an Aging Population. Drugs Aging (2015) 0.79
Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. Clin Immunol (2015) 0.78
Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation. J Ocul Pharmacol Ther (2011) 0.77
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight (2016) 0.77
The effect of FK506 and cyclosporin A on antigen-induced arthritis. Clin Exp Immunol (1991) 0.77
T-cell stimulation through the T-cell receptor/CD3 complex regulates CD2 lateral mobility by a calcium/calmodulin-dependent mechanism. Biophys J (1999) 0.77
FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. Clin Exp Immunol (1990) 0.77
The effectiveness of tacrolimus and minidose methotrexate in the prevention of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in children: a single-center study in Korea. Korean J Hematol (2012) 0.77
Improved FK506 production by the precursors and product-tolerant mutant of Streptomyces tsukubaensis based on genome shuffling and dynamic fed-batch strategies. J Ind Microbiol Biotechnol (2014) 0.76
FkbN and Tcs7 are pathway-specific regulators of the FK506 biosynthetic gene cluster in Streptomyces tsukubaensis L19. J Ind Microbiol Biotechnol (2016) 0.76
Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomedicine (2017) 0.76
FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch Dermatol Res (1995) 0.76
Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc (1987) 12.04
Hepatitis B virus genes and their expression in E. coli. Nature (1979) 10.83
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
DNA topoisomerase II is required at the time of mitosis in yeast. Cell (1985) 6.08
Magnetic control of ferroelectric polarization. Nature (2003) 5.23
A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell (1999) 4.25
Functional expression of a mammalian odorant receptor. Science (1998) 4.09
Cloning of a Streptococcus mutans glucosyltransferase gene coding for insoluble glucan synthesis. Infect Immun (1986) 4.08
On the suture of separate nerve bundles in a nerve trunk and on internal nerve plexuses. J Physiol (1917) 3.72
Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am (1994) 3.62
Isolation and one-step preparation of A2E and iso-A2E, fluorophores from human retinal pigment epithelium. Proc Natl Acad Sci U S A (1998) 3.54
Massive Dirac fermion on the surface of a magnetically doped topological insulator. Science (2010) 3.46
Collagen degradation by host-derived enzymes during aging. J Dent Res (2004) 3.30
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27
Electric-field-induced superconductivity in an insulator. Nat Mater (2008) 3.17
A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. Invest Ophthalmol Vis Sci (1999) 2.89
The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol (2001) 2.87
Epidemiological studies on patients with a persistent vegetative state. J Neurol Neurosurg Psychiatry (1977) 2.81
Yeast DNA topoisomerase II is encoded by a single-copy, essential gene. Cell (1984) 2.80
In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother (2000) 2.73
The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother (1998) 2.73
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (1998) 2.67
The predictive ability of non-invasive haemodynamic parameters for hypotension during caesarean section: a prospective observational study. Anaesthesia (2015) 2.60
Analysis of an even-skipped rescue transgene reveals both composite and discrete neuronal and early blastoderm enhancers, and multi-stripe positioning by gap gene repressor gradients. Development (1999) 2.50
Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother (1990) 2.42
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.40
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene (2006) 2.37
alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol (2000) 2.36
Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc (1987) 2.30
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) (1994) 2.28
Conversion of penicillin N to cephalosporin(s) by cell-free extracts of Cephalosporium acremonium. Biochem Biophys Res Commun (1976) 2.27
Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II. Proc Natl Acad Sci U S A (1985) 2.21
Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology (2000) 2.18
Sequence of neuron origin and neocortical laminar fate: relation to cell cycle of origin in the developing murine cerebral wall. J Neurosci (1999) 2.15
Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res (2000) 2.14
Comparison of haemodynamic responses to tracheal intubation using the Airway Scope(®) and Macintosh laryngoscope in normotensive and hypertensive patients. Anaesthesia (2011) 2.13
Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev Biol (1990) 2.11
Yeast DNA topoisomerase II. An ATP-dependent type II topoisomerase that catalyzes the catenation, decatenation, unknotting, and relaxation of double-stranded DNA rings. J Biol Chem (1982) 2.09
Nucleotide sequence of the streptothricin acetyltransferase gene from Streptomyces lavendulae and its expression in heterologous hosts. J Bacteriol (1987) 2.08
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Mechanism of cell detachment from temperature-modulated, hydrophilic-hydrophobic polymer surfaces. Biomaterials (1995) 2.04
Internet-based program for automatic discrimination of dermoscopic images between melanomas and Clark naevi. Br J Dermatol (2004) 1.99
Calcium signalling in the guidance of nerve growth by netrin-1. Nature (2000) 1.96
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother (2001) 1.96
Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology (1994) 1.96
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother (2000) 1.93
Dental pulp cells for induced pluripotent stem cell banking. J Dent Res (2010) 1.92
Unusual widening of Virchow-Robin spaces: MR appearance. AJNR Am J Neuroradiol (1995) 1.92
The roles of the C-terminal domain and type III domains of chitinase A1 from Bacillus circulans WL-12 in chitin degradation. J Bacteriol (1994) 1.91
Discovery of superconductivity in KTaO₃ by electrostatic carrier doping. Nat Nanotechnol (2011) 1.89
From a single-band metal to a high-temperature superconductor via two thermal phase transitions. Science (2011) 1.87
New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot (Tokyo) (1996) 1.87
Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration. Cell (1996) 1.85
Cell output, cell cycle duration and neuronal specification: a model of integrated mechanisms of the neocortical proliferative process. Cereb Cortex (2003) 1.82
Sodic soils reclaimed with by-product from flue gas desulfurization: corn production and soil quality. Environ Pollut (2001) 1.76
Tetrodotoxin. Tetrahedron (1965) 1.75
Laparoscopic omental patch repair for perforated peptic ulcer. Ann Surg (1995) 1.74
Observations on the atrophy of denervated muscle. J Physiol (1918) 1.74
Lack of correlation between the reduction of sevoflurane MAC and the cerebellar cyclic GMP concentrations in mice treated with 7-nitroindazole. Anesthesiology (1998) 1.73
The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. J Biol Chem (1984) 1.72
High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nat Biotechnol (2001) 1.72
Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology (1974) 1.70
Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst (1986) 1.68
A prokaryotic gene cluster involved in synthesis of lysine through the amino adipate pathway: a key to the evolution of amino acid biosynthesis. Genome Res (1999) 1.65
Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65
Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis. J Rheumatol (1988) 1.63
Emergence agitation after sevoflurane versus propofol in pediatric patients. Anesth Analg (2000) 1.63
Synthesis of oligothymidylates and nucleoside cyclic phosphates by oxidation-reduction condensation. J Am Chem Soc (1972) 1.63
Characterization of a gene responsible for the Na+/H+ antiporter system of alkalophilic Bacillus species strain C-125. Mol Microbiol (1994) 1.63
Two pathways in the biosynthesis of cadystins (gamma EC)nG in the cell-free system of the fission yeast. Biochem Cell Biol (1991) 1.62
A novel zinc finger protein, zic, is involved in neurogenesis, especially in the cell lineage of cerebellar granule cells. J Neurochem (1994) 1.62
Hyperbaric oxygen reduces infarct volume in rats by increasing oxygen supply to the ischemic periphery. Crit Care Med (2000) 1.62
Development of a host-vector system in a Rhodococcus strain and its use for expression of the cloned nitrile hydratase gene cluster. J Gen Microbiol (1992) 1.60
Primary structure of AfsR, a global regulatory protein for secondary metabolite formation in Streptomyces coelicolor A3(2). Gene (1990) 1.57
Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes (2001) 1.57
Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol (1999) 1.57
Trithorax- and Polycomb-group response elements within an Ultrabithorax transcription maintenance unit consist of closely situated but separable sequences. Mol Cell Biol (1999) 1.56
Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci U S A (1997) 1.56
New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot (Tokyo) (1996) 1.56
Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med (1998) 1.55
Normal variations of the temporal bone on high-resolution CT: their incidence and clinical significance. Clin Radiol (1995) 1.55
Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J (1998) 1.54